Sanofi expands insulin program to $35 monthly cap for all US patients

Sanofi (NASDAQ: SNY) announced it will expand its Insulins Valyou Savings Program to offer a 30-day supply of any Sanofi insulin for $35 to all patients in the United States with a valid prescription, according to a company statement.

The program, previously available only to people without health insurance, will extend to all Americans regardless of insurance status, including those with commercial insurance or Medicare. The expansion takes effect January 1, 2026.

"Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter," said Adam Gluck, Head of US Corporate Affairs at Sanofi. "At Sanofi, we share his objective and believe that no one should struggle to afford their insulin."

Under the expanded program, patients can purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for a fixed monthly price of $35. The program operates at most pharmacies across the US, including independent and rural pharmacies.

"Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences," said Olivier Bogillot, Head of General Medicines, North America, Sanofi.

Patients can enroll through Sanofi Patient Connection or by calling 1-888-847-4877. The program covers all Sanofi insulin products and will be implemented nationwide.

You May Also Be Interested In

• BofA Securities Starts Mobility Global (MBGL) at Neutral
• European Commission closes antitrust probe into RTX unit
• Cinemo, Dolby, and SmashLabs partner on in-car gaming system